Clinical trial · Observational
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Study to Surveil and Track the Outcomes of Chronic Latent EBV Infection Based on Healthy Volunteers Undergoing Routine Inspection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EBV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| peripheral EBV-DNA load | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- peripheral EBV-DNA load
- description
- subjects with high load (\>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
- interventionNames
- Other: peripheral EBV-DNA load
Primary outcomes (1)
- measure
- hematological malignancies
- timeFrame
- Five years or more if necessary
- description
- including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma, and Chronic active Epstein-Barr virus infection (CAEBV).
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. immunocompetent subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination 2. Willing to be followed up by telephone or face-to-face interview Exclusion Criteria: 1. Subjects with defined immunodeficiency 2. Subjects who have taken or are going to take immunosuppressive drugs. 3. Subjects Diagnosed a validated hematopathy 4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year. 5. psychological illness which does not allow subjects to understand the study and participate following his own free will 6. Pregnant woman 7. no written informed consent
References
Publications (0)
Data not yet available